Testosterone May Fight As Well As Feed Prostate Cancers

October 15, 1996

In a surprising finding that suggests radical changes in the way prostate cancer is managed, researchers at the University of Chicago Medical Center have shown in laboratory experiments that the male hormone testosterone, which fuels prostate cancers early in their growth, can in later stages cause tumors to stop growing or even shrink.

The finding is reported in the October 15 issue of the Proceedings of the National Academy of Sciences.

Doctors have routinely used surgical or chemical castration to slow the growth of cancer that has spread beyond the gland since 1941, when University of Chicago urologist Charles Huggins showed that prostate cancers require testosterone for growth and demonstrated the effectiveness of removing the hormone. Huggins received the Nobel Prize for this work in 1966.

Men treated with anti-hormone therapy often show dramatic improvement. But within a few years, the tumors regrow because the cells lose their dependency on testosterone and are able to thrive without it.

Now a researcher who was a colleague of Huggins for more than 30 years has shown that those tumors that no longer depend on testosterone may in fact be sensitive to it.

Shutsung Liao, Ph.D., professor in the Ben May Institute for Cancer Research, and his co-workers showed in laboratory mice that testosterone can shrink experimental human prostate tumors that no longer depend on the hormone.

The finding suggests that testosterone supplementation, perhaps delivered by a patch, may be beneficial for certain types of prostate cancer, and that prolonged use of anti-hormone drugs, like Lupron, Zoladex and Proscar should no longer be routine.

"This is an interesting preliminary finding that may make us rethink our approach to therapy," said Glenn Gerber, M.D., a University of Chicago urologist not connected to the study.

Prostate cancer is the most commonly diagnosed cancer in American men, with 317,000 new cases and 41,400 deaths expected in 1996. Although several treatment options are available for cancers confined to the gland, only anti-hormone therapy has been effective for slowing the growth of distant tumors.

"Although three-quarters of prostate cancer patients can have their tumors shrunk by castration or anti-hormone drug therapy, most of these cancers recur in one to three years and are then no longer dependent on hormones," Liao said. "Currently, once the tumor becomes independent of testosterone, there is no way to treat it."

Standard chemotherapy agents are not very effective against prostate cancer. The goal, according to Gerber, is to improve long-term management of the disease.

"While this new approach is not likely to cure anyone," said Gerber, "it suggests that we may be able to restart the survival clock, perhaps several times, not just by starving cells that need testosterone but also by feeding it to cells that gag on it."

To simulate the recurrence of hormone-independent cancer, research associate John Kokontis grew human prostate cancer cells in the laboratory and weaned them off testosterone, a process that required repeated re-culturing of the cells over a two-year period. These cells, now capable of growing testosterone-free, were used to seed tumors in laboratory mice. The researchers looked at the effect of testosterone on these mice and compared them to mice implanted with tumors that need testosterone.

The researchers found that adding even low levels of testosterone could shrink established tumors of hormone-independent cells. Removing the added testosterone, or adding testosterone-lowering drugs, caused the tumors to regrow.

The researchers dedicated the report to Huggins, who turned 95 last month and has been in ill health. The work was funded by the National Institutes of Health.

Authors of the report in addition to Liao and Kokontis are visiting professor Yoshihisa Umekita and senior research associate Richard Hiipakka.

University of Chicago Medical Center

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.